Document is current
Any future updates will be listed below
-
Authors
Bonaventura, Jordi https://orcid.org/0000-0002-4745-0151
Eldridge, Mark A. G. https://orcid.org/0000-0003-4292-6832
Hu, Feng https://orcid.org/0000-0003-4176-5694
Gomez, Juan L.
Sanchez-Soto, Marta
Abramyan, Ara M.
Lam, Sherry
Boehm, Matthew A.
Ruiz, Christina
Farrell, Mitchell R.
Moreno, Andrea
Galal Faress, Islam Mustafa
Andersen, Niels
Lin, John Y. https://orcid.org/0000-0002-1723-4597
Moaddel, Ruin
Morris, Patrick J.
Shi, Lei https://orcid.org/0000-0002-4137-096X
Sibley, David R. https://orcid.org/0000-0002-0624-962X
Mahler, Stephen V. https://orcid.org/0000-0002-8698-0905
Nabavi, Sadegh
Pomper, Martin G.
Bonci, Antonello
Horti, Andrew G.
Richmond, Barry J. https://orcid.org/0000-0002-8234-1540
Michaelides, Michael https://orcid.org/0000-0003-0398-4917
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (ZIA000069)
- License Information
-
More Information
Article History
Received: 13 March 2019
Accepted: 13 August 2019
First Online: 11 October 2019
Competing interests
: M.M. is a cofounder and owns stock in Metis Laboratories. J.B., J.L.G., F.H., M.S.S., A.G.H., M.G.P., and M.M. are listed as inventors on an application (62/627,527) filed with the U.S. Patent Office regarding the novel DREADD compounds described herein. Remaining authors declare no competing interest.
